Clinical Trials on B Cell Malignancy in China

Total 5742 results

Ruijin Hospital

Unknown

Lenalidomide Based Immunotherapy in the Treatment of DLBCL

Diffuse Large B Cell Lymphoma

China
Sinocelltech Ltd.

Unknown

A Study Comparing the Efficiency and Safety of S-CHOP(Cyclophosphamide, Hydroxydaunomycin, Oncovin, and Prednisone) Versus R-CHOP in Untreated CD20(Cluster of Differentiation Antigen 20)-Positive DLBCL Patients

Diffuse Large B Cell Lymphoma

China
Peking Union Medical College Hospital

Unknown

Effectiveness of Circulating DNA for Predicting the Relapse and Overall Survival in NHL Patients

Diffuse Large B Cell Lymphoma | Peripheral T Cell Lymphoma

China
Peking University People's Hospital
Peking University Cancer Hospital & Institute

Recruiting

Frontline of ASCT in High-risk DLBCL (Essential)

Diffuse Large B Cell Lymphoma

China
Changhai Hospital
Nanjing Enricnk Biotech Co., Ltd

Recruiting

The Study of Anti-CD19 CAR NK Cells in the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma

Diffuse Large B Cell Lymphoma

China
Ruijin Hospital

Recruiting

Mechanism of Resistance to GNC-038 in Relapsed and Refractory Diffuse Large B-cell Lymphoma

Diffuse Large B Cell Lymphoma

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Not yet recruiting

A Study of Anlotinib Hydrochloride Capsules in Subjects With Diffuse Large B-Cell Lymphoma

Diffuse Large B-cell Lymphoma

China
Ruijin Hospital

Active, not recruiting

Zanubrutinib, Lenalidomide and Rituximab (ZR2) in Elderly Treatment-naive Patients With Diffuse Large B-cell Lymphoma (DLBCL)

Diffuse Large B Cell Lymphoma

China
Ruijin Hospital

Active, not recruiting

Study Evaluating the Safety and Efficacy of iR2 in Untreated and Unfit Elderly Patients With DLBCL

Diffuse Large B Cell Lymphoma

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Study Comparing the Efficacy and Safety Between I-CHOP and R-CHOP in Untreated CD20-Positive Diffuse Large B-cell Lymphoma Patients

Diffuse, Large B-Cell, Lymphoma

China
Fudan University

Terminated

Dose-adjusted EPOCH-R in MYC Positive DLBCL

Diffuse Large B-cell Lymphoma

China
Fudan University

Unknown

Interim PET/CT Guided Cycle Numbers of R-CHOP in DLBCL

Diffuse Large B-cell Lymphoma

China
Kunming Hope of Health Hospital

Withdrawn

Anti-CD19 Universal CAR-NK Cells Therapy Combined With HSCT for B Cell Hematologic Malignancies

B-cell Lymphoma | B-cell Leukemia

China
Second Affiliated Hospital, School of Medicine,...

Completed

Clinical Follow-up Study of CD19 CAR-T Expressing IL7 and CCL19 for Relapsed or Refractory B Cell Lymphoma

Transformed Follicular Lymphoma | Mantle Cell Lymphoma | Diffuse Large B-cell Lymphoma | Primary Mediastinal Large B-cell Lymphoma

China
The First Hospital of Jilin University
CSPC Ouyi Pharmaceutical Co., Ltd.

Not yet recruiting

The Efficacy and Safety of the RCMOP Sequential Therapy as a First-line Treatment for Patients With Intermediate-to-high Risk Diffuse Large B-cell Lymphoma Who Had Incomplete Remission.

Diffuse Large B-cell Lymphoma

China
First Affiliated Hospital of Wenzhou Medical University

Recruiting

The Efficacy and Safety of ZR2 Versus R-CHOP-like Regimen for Elderly Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma.

Diffuse Large B Cell Lymphoma

China
Chongqing Precision Biotech Co., Ltd

Recruiting

CD19 and CD22 Targeted CAR-T Cell Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma

Lymphoma, B-Cell | Leukemia, B-cell

China
Second Affiliated Hospital, School of Medicine,...

Completed

Combining Intratumoral Metabolic Heterogeneity and Dissemination Feature (Dmax) on 18F-FDG PET/CT Improves Prognosis Prediction in DLBCL

Diffuse Large B-cell Lymphoma

China
First Affiliated Hospital of Zhejiang University

Unknown

Chidamide With R-CHOP Regimen for DLBCL Patients (DLBCL)

Diffuse Large B Cell Lymphoma

China
Mingzhi Zhang

Unknown

Treatment of Diffuse Large B Cell Lymphoma

Diffuse Large B Cell Lymphoma

China
Sun Yat-sen University

Unknown

A Study of Improving the Efficacy of Treatment in Diffused Large B Cell Lymphoma Patients

Diffuse Large B-cell Lymphoma

China
Shanghai CP Guojian Pharmaceutical Co., Ltd.

Completed

Study of Recombinant Human-Mouse Chimeric Anti-CD20 Monoclonal Antibody to Treat Non-hodgkin's Lymphoma

Diffuse Large B Cell Lymphoma

China
Henan Cancer Hospital
Henan Hualong Biotechnology Company

Unknown

Cord Blood Derived CAR-T Cells in Refractory/Relapsed B Cell Malignancies

B Cell Lymphoma | B Cell Leukemia | Refractory | Relapsed

China
Shandong Provincial Hospital

Recruiting

Orelabrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma

Mantle Cell Lymphoma | Diffuse Large B-cell Lymphoma | High Grade B-Cell Lymphoma, Not Otherwise Specified | High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements | B-cell NonHodgkin Lymphoma

China
BeBetter Med Inc

Active, not recruiting

Study of BEBT-908 in the Relapsed or Refractory Diffuse Large B-cell Lymphoma Subjects

Relapsed or Refractory Diffuse Large B-cell Lymphoma

China
BeBetter Med Inc

Recruiting

Study of BEBT-908 Combined With Drugs in the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Relapsed/Refractory Diffuse Large B-Cell Lymphoma

China
Cancer Institute and Hospital, Chinese Academy...

Unknown

Toripalimab Combine With Rituximab for Treatment of Relapsed Refractory CD20 Positive Diffuse Large B-cell Lymphoma

Diffuse Large B-cell Lymphoma | Rituximab | Toripalimab

China
Zhujiang Hospital
Shenzhen Geno-Immune Medical Institute

Withdrawn

Interleukin-2 Following 4SCAR19/22 T Cells Targeting Refractory and/or Recurrent B Cell Malignancies

B-Cell Leukemia | B-Cell Lymphoma

China
Ruijin Hospital

Not yet recruiting

Real-World Study of DLBCL With Different Genetic Subtypes

Lymphoma | DLBCL - Diffuse Large B Cell Lymphoma

China
Fudan University
Xiangya Hospital of Central South University; Shanghai Changzheng Hospital; Baotou...

Active, not recruiting

A Study to Evaluate Efficacy and Safety of Zanubrutinib With R-CHOP in Newly Diagnosed Non-GCB DLBCL Patients With Double Expression

Diffuse Large B-cell Lymphoma(DLBCL)

China
Beijing Tongren Hospital

Recruiting

CD19/CD22 Bispecific CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma or Acute Lymphoblastic Leukemia

B-cell Lymphoma | Diffuse Large B Cell Lymphoma | B-cell Acute Lymphoblastic Leukemia

China
Zhejiang Cancer Hospital

Recruiting

A-RGEMOX in the Treatment of Early Relapsed/Refractory DLBCL

Diffuse Large B-cell Lymphoma Recurrent | Diffuse Large B Cell Lymphoma Refractory

China
The First Affiliated Hospital with Nanjing Medical...

Unknown

Lenalidomide, Rituximab, Gemcitabine, Oxaliplatin and Dexamethasone in Relapse and Refractory DLBCL (R2-GOD)

Diffuse Large B-cell Lymphoma Recurrent | Diffuse Large B Cell Lymphoma Refractory

China
Nanfang Hospital of Southern Medical University
Peking University People's Hospital; Guangzhou First People's Hospital; Sun Yat-Sen... and other collaborators

Unknown

BUCY+VP-16 vs BUCY Conditioning Regimen for DLBCL Undergoing Auto-HSCT

Conditioning | Diffuse Large B-cell Lymphoma | Autologous Hematopoietic Stem Cell Transplantation

China
LanZhou University
Beigene (Beijing) Biotechnology Co., Ltd

Not yet recruiting

Zanubrutinib in Maintenance Therapy of DLBCL Patients With Initial Remission

Diffuse Large B-cell Lymphoma (DLBCL)

China
Chengdu Zenitar Biomedical Technology Co., Ltd

Completed

Study of Prilinostat Mesylate for Injection in the Treatment of Relapsed or Refractory B Cell-related Tumor-predominant

Diffuse Large B Cell Lymphoma，DLBCL

China
He Huang
Leman Biotech Co., Ltd

Recruiting

Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r DLBCL Clinical Research

Diffuse Large B-cell Lymphoma

China
Huazhong University of Science and Technology

Recruiting

Zanubrutinib Combined With R-CHOP in the Treatment of Newly Diagnosed DLBCL With p53 Protein Expression

Diffuse Large B Cell Lymphoma

China
Liaoning Tumor Hospital & Institute

Not yet recruiting

Zanubrutinib Combined With R-CHOP Regimen in the Treatment of Newly Diagnosed DLBCL With High-risk Factors

Diffuse Large B Cell Lymphoma

China
The First Affiliated Hospital of Soochow University

Recruiting

Pro-miniCHOP-like Regimen for Treatment-naive Elderly Patients

Diffuse Large B Cell Lymphoma

China
Nanfang Hospital of Southern Medical University

Not yet recruiting

Lenalidomide Plus R-CHOP for CNS Relapse Prophylaxis in Diffuse Large B-cell Lymphoma

Diffuse Large B Cell Lymphoma

China
Wuhan University

Recruiting

The Palliative Benefit of Involved-site Radiotherapy for Patients With Advanced-stage Diffuse Large B-cell Lymphoma

Diffuse Large B-cell Lymphoma

China
Wuhan University

Recruiting

Efficacy of Consolidative Involved-site Radiotherapy for Patients With Limited-stage Diffuse Large B-cell Lymphoma

Diffuse Large B-cell Lymphoma

China
Henan Cancer Hospital

Active, not recruiting

R-CHOP Combined With Lenalidomide in the First-line Treatment for Patients With Diffuse Large B Cell Lymphoma

Diffuse Large B Cell Lymphoma

China
Second Affiliated Hospital, School of Medicine,...

Enrolling by invitation

CD19 CAR-T Expressing IL7 and CCL19 Combined With PD1 mAb for Relapsed or Refractory Diffuse Large B Cell Lymphoma (CICPD)

Diffuse Large B-cell Lymphoma

China
Sun Yat-sen University

Unknown

A Novel Prognostic Model of NPI for Risk-Predicting and Clinical Decision-making in Diffuse Large B-Cell Lymphoma in the Rituximab Era

Diffuse Large B Cell Lymphoma

China
Henan Cancer Hospital

Unknown

Chidamide Combined With VDDT Regimen in the Relapse and Refractory Diffuse Large B Cell Lymphoma

Diffuse Large B-cell Lymphoma

China
Anhui Provincial Hospital
Leman Biotech Co., Ltd

Recruiting

Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r DLBCL Clinical Research

Diffuse Large B-cell Lymphoma

China
Jianfeng Zhou
CSPC Ouyi Pharmaceutical Co., Ltd.

Not yet recruiting

Mitoxantrone Hydrochloride Liposome Combined With Rituximab and Lenalidomide (M+R2) in Patients With Relapsed and Refractory Diffuse Large B-Cell Lymphoma

Diffuse Large B-cell Lymphoma

China
Zhejiang Cancer Hospital

Recruiting

ZR2 Followed by Immunochemotherapy in Elderly Patients With Newly-diagnosed DLBCL

Diffuse Large B Cell Lymphoma

China

Clinical Trials on B Cell Malignancy in China

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Togo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations